Aperio Group LLC cut its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 1.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,365 shares of the medical instruments supplier’s stock after selling 863 shares during the period. Aperio Group LLC owned approximately 0.06% of West Pharmaceutical Services worth $4,271,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Acrospire Investment Management LLC bought a new position in shares of West Pharmaceutical Services in the second quarter valued at approximately $113,000. Citigroup Inc. boosted its holdings in shares of West Pharmaceutical Services by 95.1% in the second quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock valued at $148,000 after acquiring an additional 765 shares in the last quarter. Wolverine Trading LLC bought a new position in shares of West Pharmaceutical Services in the second quarter valued at approximately $200,000. Nomura Holdings Inc. bought a new position in shares of West Pharmaceutical Services in the second quarter valued at approximately $201,000. Finally, Bradley Foster & Sargent Inc. CT bought a new position in shares of West Pharmaceutical Services in the second quarter valued at approximately $212,000. Institutional investors and hedge funds own 90.10% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “West Pharmaceutical Services, Inc. (WST) Stake Lessened by Aperio Group LLC” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2017/11/09/west-pharmaceutical-services-inc-wst-stake-lessened-by-aperio-group-llc.html.
Several research firms have recently issued reports on WST. Stephens began coverage on shares of West Pharmaceutical Services in a report on Tuesday, October 3rd. They issued an “equal weight” rating and a $99.00 price objective for the company. BidaskClub cut shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Wednesday, September 27th. Wells Fargo & Company raised their target price on shares of West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. Finally, Bank of America Corporation cut shares of West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 target price for the company. in a report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $106.00.
Shares of West Pharmaceutical Services, Inc. (NYSE WST) opened at $101.24 on Thursday. The firm has a market cap of $7,502.52, a P/E ratio of 43.55, a P/E/G ratio of 2.16 and a beta of 1.14. West Pharmaceutical Services, Inc. has a 1-year low of $73.69 and a 1-year high of $103.36. The company has a current ratio of 2.59, a quick ratio of 1.87 and a debt-to-equity ratio of 0.15.
West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.14. The firm had revenue of $398.20 million during the quarter, compared to analysts’ expectations of $386.02 million. West Pharmaceutical Services had a net margin of 12.12% and a return on equity of 14.47%. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period last year, the firm posted $0.53 earnings per share. equities research analysts predict that West Pharmaceutical Services, Inc. will post 2.76 EPS for the current fiscal year.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.